Duality of Interest. L.L. received speaker fees from Abbott, AstraZeneca, Eli Lilly, Medtronic, Menarini, Novo Nordisk, Roche Diabetes Care, and Sanofi Aventis and provided advisory services to Abbott, AstraZeneca, Eli Lilly, Novo Nordisk, Roche Diabetes Care, Sanofi Aventis, and Takeda. F.G. received research support from Eli Lilly, LifeScan, and Takeda and served as a consultant and author for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. I.C., A.C., and F.G. wrote the manuscript. I.C. and A.C. performed the statistical analysis and created the figure. L.L. and F.G. reviewed the manuscript. F.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.